RecruitingNot ApplicableNCT06234592

The Effect of Vasopressor Therapy on Renal Perfusion in Septic Shock

The Effect of Vasopressor Therapy on Renal Perfusion in Patients With Septic Shock - a Mechanistically Focussed Randomized Control Study


Sponsor

King's College Hospital NHS Trust

Enrollment

45 participants

Start Date

Jan 5, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

Acute kidney injury (AKI) is a common complication of septic shock and together these conditions carry a high mortality risk. In septic patients who develop severe AKI renal cortical perfusion is deficient despite normal macrovascular organ blood flow. This intra-renal perfusion abnormality may be amenable to pharmacological manipulation, which may offer mechanistic insight into the pathophysiology of septic AKI. The aim of the current study is to investigate the effects of vasopressin and angiotensin II on renal microcirculatory perfusion in a cohort of patients with septic shock.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Angiotensin II, a drug called Norepinephrine, and others for people with acute kidney injury and septic shock. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGAngiotensin II

Angiotensin II infusion

DRUGVasopressin

Vasopressin infusion

DRUGNorepinephrine

Standard care vasopressor therapy, norepinephrine infusion


Locations(1)

King's College Hospital

London, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06234592


Related Trials